Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
NCT04992858 · Sunshine Lake Pharma Co., Ltd. · PHASE2 · withdrawn · last registry update 2026-05-14 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn proactively due to the company's development strategy adjustment and changes in the drug R\&D direction.” | Open Targets' class: business administrative | Registry record, Sunshine Lake Pharma Co., Ltd. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-02Results posted on the registry: Novartis Pharmaceuticals, Capmatinib 150 mg + Capmatinib 200 mg (NCT05110196)
- 2026-09-11Phase 3 first posted: Guangzhou JOYO Pharma Co., Ltd, JYP0322 Tablets + Crizotinib Capsules (NCT07816380)
- 2026-05-28Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Nivolumab (NCT04514484)
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-03-27Results posted on the registry: Novartis Pharmaceuticals, Capmatinib (NCT04677595)
- 2026-02-02Results posted on the registry: Janssen Research & Development, LLC, Lazertinib + Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (NCT05388669)
- 2026-01-13Results posted on the registry: Exelixis, XL184 + erlotinib (NCT00596648)
- 2025-10-24Results posted on the registry: AbbVie, Telisotuzumab Vedotin (NCT05513703)
- 2025-10-24Also stopped (terminated): AbbVie, Telisotuzumab Vedotin (NCT05513703)
- 2025-10-20Results posted on the registry: Janssen Research & Development, LLC, Dexamethasone + Montelukast (NCT05663866)
- 2025-10-16Also stopped (terminated): Novartis Pharmaceuticals, capmatinib (NCT04926831)
- 2025-05-16Also stopped (terminated): Novartis Pharmaceuticals, Capmatinib + Docetaxel (NCT04427072)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision